Kidney Patients Hurt When Doctors Must Push Amgen’s Aranesp - BusinessWeek: "Diabetic patients with chronic kidney disease are more likely to suffer heart complications or die if they need higher doses of Amgen Inc.’s Aranesp to reach current treatment goals, researchers said.
Doctors have been reducing the target range for red blood cells in anemia patients who use drugs such as Aranesp after studies found patients at the high end were at the greatest risk of harm. Individuals who don’t respond well to Aranesp, used to bolster the number of red blood cells, and are given more of the medicine to get to the goal, are most vulnerable, an analysis released today found.
No comments:
Post a Comment